Olthof Ester P, Bergink-Voorthuis Brenda J, Wenzel Hans H B, Mongula Jordy, van der Velden Jacobus, Spijkerboer Anje M, Adam Judit A, Bekkers Ruud L M, Beltman Jogchum J, Slangen Brigitte F M, Nijman Hans W, Smolders Ramon G V, van Trommel Nienke E, Zusterzeel Petra L M, Zweemer Ronald P, Stalpers Lukas J A, Mom Constantijne H, van der Aa Maaike A
Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, DT, Utrecht, 3511, The Netherlands.
Department of Gynecological Oncology, Amsterdam University Medical Center, Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam, The Netherlands.
Insights Imaging. 2024 Feb 8;15(1):36. doi: 10.1186/s13244-023-01589-1.
Imaging is increasingly used to assess lymph node involvement in clinically early-stage cervical cancer. This retrospective study aimed to evaluate the diagnostic accuracy of MRI, CT, and [F]FDG-PET-CT.
Women with International Federation of Gynaecology and Obstetrics (FIGO) 2009 stage IA2-IIA cervical cancer and pretreatment imaging between 2009 and 2017 were selected from the Netherlands Cancer Registry. Patient-based and region-based (i.e. pelvic and common iliac) nodal status was extracted from radiology reports. Pathology results were considered the reference standard for calculating accuracy indices. Multiple imputation was used for missing pathology to limit verification bias risk.
Nodal assessment was performed in 1676 patients with MRI, 926 with CT, and 379 with [F]FDG-PET-CT, with suspicious nodes detected in 17%, 16%, and 48%, respectively. [F]FDG-PET-CT was used to confirm MRI/CT results in 95% of patients. Pathology results were imputed for 30% of patients. [F]FDG-PET-CT outperformed MRI and CT in detecting patient-based nodal metastases with sensitivities of 80%, 48%, and 40%, and AUCs of 0.814, 0.706, and 0.667, respectively, but not in specificity: 79%, 92%, and 92%. Region-based analyses showed similar indices in the pelvic region, but worse performance in the common iliac region with AUCs of 0.575, 0.554, and 0.517, respectively.
[F]FDG-PET-CT outperformed MRI and CT in detecting nodal metastases, which may be related to its use as a verification modality. However, MRI and CT had the highest specificity. As MRI is generally performed routinely to assess local and regional spread of cervical cancer, [F]FDG-PET-CT can be used to confirm suspicious nodes.
Accurate assessment of the nodal status in clinically early-stage cervical cancer is essential for tumour staging, treatment decision making and prognosis.
• The accuracy of MRI, CT or [F]FDG-PET-CT for nodal staging in early cervical cancer is a subject of discussion. • Overall, [F]FDG-PET-CT outperformed MRI, followed by CT, when used as a verification modality. • Staging with MRI and the addition of [F]FDG-PET-CT to verify high-risk cases seems to be a good approach.
影像学检查越来越多地用于评估临床早期宫颈癌的淋巴结受累情况。本回顾性研究旨在评估MRI、CT和[F]FDG-PET-CT的诊断准确性。
从荷兰癌症登记处选取2009年至2017年间患有国际妇产科联盟(FIGO)2009分期IA2-IIA期宫颈癌且有治疗前影像学检查的女性。基于患者和基于区域(即盆腔和髂总)的淋巴结状态从放射学报告中提取。病理结果被视为计算准确性指标的参考标准。采用多重填补法处理缺失的病理结果,以降低验证偏倚风险。
对1676例患者进行了MRI淋巴结评估,926例进行了CT评估,379例进行了[F]FDG-PET-CT评估,分别有17%、16%和48%检测到可疑淋巴结。95%的患者使用[F]FDG-PET-CT来确认MRI/CT结果。30%的患者病理结果采用了填补法。在检测基于患者的淋巴结转移方面,[F]FDG-PET-CT优于MRI和CT,其敏感性分别为80%、48%和40%,AUC分别为0.814、0.706和0.667,但在特异性方面并非如此:分别为79%、92%和92%。基于区域的分析显示盆腔区域的指标相似,但在髂总区域表现较差,AUC分别为0.575、0.554和0.517。
在检测淋巴结转移方面,[F]FDG-PET-CT优于MRI和CT,这可能与其作为验证手段的应用有关。然而,MRI和CT具有最高的特异性。由于通常会常规进行MRI以评估宫颈癌的局部和区域扩散情况,[F]FDG-PET-CT可用于确认可疑淋巴结。
准确评估临床早期宫颈癌的淋巴结状态对于肿瘤分期、治疗决策和预后至关重要。
• MRI、CT或[F]FDG-PET-CT在早期宫颈癌淋巴结分期中的准确性是一个有争议的话题。• 总体而言,当用作验证手段时,[F]FDG-PET-CT优于MRI,其次是CT。• 用MRI进行分期并加用[F]FDG-PET-CT来验证高危病例似乎是一种很好的方法。